EUVIMEDEUVIMED entdecken
Übersichtsarbeit

O-GlcNAcylation in cancer development and immunotherapy

Xue-Fen He, Xiaoli Hu, Gao-Jing Wen, Zhiwei Wang, Wen-Jing Lin

Cancer Letters · 2023-07 · 566 · 216258

DOI: 10.1016/j.canlet.2023.216258 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Letters, 2023-07. Verfasst von Xue-Fen He und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Wenzhou Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou People's Hospital, Wenzho…. Hauptthemen laut MEDLINE: Protein Processing, Post-Translational, Neoplasms. Die Arbeit wurde bisher 116-mal zitiert (Crossref) und nennt 187 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

O-linked β-D-N-acetylglucosamine (O-GlcNAc), as a posttranslational modification (PTM), is a reversible reaction that attaches β-N-GlcNAc to Ser/Thr residues on specific proteins by O-GlcNAc transferase (OGT). O-GlcNAcase (OGA) removes the O-GlcNAc from O-GlcNAcylated proteins. O-GlcNAcylation regulates numerous cellular processes, including signal transduction, the cell cycle, metabolism, and energy homeostasis. Dysregulation of O-GlcNAcylation contributes to the development of various diseases, including cancers. Accumulating evidence has revealed that higher expression levels of OGT and hyper-O-GlcNAcylation are detected in many cancer types and governs glucose metabolism, proliferation, metastasis, invasion, angiogenesis, migration and drug resistance. In this review, we describe the biological functions and molecular mechanisms of OGT- or O-GlcNAcylation-mediated tumorigenesis. Moreover, we discuss the potential role of O-GlcNAcylation in tumor immunotherapy. Furthermore, we highlight that compounds can target O-GlcNAcylation by regulating OGT to suppress oncogenesis. Taken together, targeting protein O-GlcNAcylation might be a promising strategy for the treatment of human malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Processing, Post-TranslationalNeoplasmsHumansProteinsSignal TransductionImmunotherapyN-AcetylglucosaminyltransferasesAcetylglucosamine

Stichwörter der Autor:innen

Drug resistanceOGAOGTPD-1PD-L1

Substanzen

ProteinsN-AcetylglucosaminyltransferasesAcetylglucosamine

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Wenzhou Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou People's Hospital, Wenzhou, 325000, Zhejiang, China.
  • Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Department of Biochemistry and Molecular Biology, School of Laboratory Medicine, Bengbu Medical College, Anhui, China; Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical Universit…
  • Department of Obstetrics and Gynecology, Wenzhou Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou People's Hospital, Wenzhou, 325000, Zhejiang, China. Electronic address: 15990703413@163.com.

Zitieren

APA

He, X. F., Hu, X., Wen, G. J., Wang, Z., & Lin, W. J. (2023). O-GlcNAcylation in cancer development and immunotherapy. Cancer Letters, 566, 216258. https://doi.org/10.1016/j.canlet.2023.216258

Vancouver

He XF, Hu X, Wen GJ, Wang Z, Lin WJ. O-GlcNAcylation in cancer development and immunotherapy. Cancer Letters. 2023;566:216258. doi:10.1016/j.canlet.2023.216258

BibTeX
@article{He2023,
  author = {He, Xue-Fen and Hu, Xiaoli and Wen, Gao-Jing and Wang, Zhiwei and Lin, Wen-Jing},
  title = {O-GlcNAcylation in cancer development and immunotherapy},
  journal = {Cancer Letters},
  year = {2023},
  volume = {566},
  pages = {216258},
  doi = {10.1016/j.canlet.2023.216258}
}
Kostenlos starten →